Helix
Helix, St. Luke's University Health Network Partner on Population Health Study
The program initially aims to enroll 100,000 participants over four years, with consenting individuals receiving information about their potential risks for serious health conditions.
An analysis of whole-exome sequencing results presented at AACR suggests many people with hereditary cancer risk variants don't fall under current NCCN guidelines.
Mayo Clinic Laboratories, Helix Collaborate to Offer Biopharma Lab Services
The partnership makes Mayo's tests and pathology services and Helix's Exome+ assay available to biopharma customers.
Qiagen, Helix Partner for Hereditary Disease CDx Development
The partnership will leverage Helix's whole-exome sequencing platform and incorporate Qiagen's biopharma relationships, NGS capabilities, and global regulatory expertise.
Helix, CDC Partner to Study Genetics of Vaccine Effectiveness
The firm said the contract extends its public-private partnership with the US Centers for Disease Control and Prevention.